Alesi Surgical, a medical technology company dedicated to improving operating room safety, has successfully raised £7 million in a new funding round. The investment was led by IW Capital, with significant participation from existing backers including Mercia Ventures and IP Group. This capital injection is set to fuel the international expansion and further development of Alesi's innovative Ultravision platform for surgical smoke management.
Addressing a Persistent Operating Room Hazard
Surgical smoke, a byproduct generated in approximately 90% of all surgical procedures, poses a significant challenge in operating theatres. This plume impairs surgeons' visibility and exposes healthcare staff to a cocktail of harmful aerosols, including viable viruses, bacteria, and toxic chemicals. The issue presents both short-term infection risks and long-term health hazards for everyone in the room.
Historically, the adoption of smoke management solutions has been hindered by their design, with many systems being cumbersome and disruptive to surgical workflows. Surgeons have often described these traditional suction and filtration devices as inefficient, bulky, and noisy. Consequently, their use has been limited despite the well-documented dangers of surgical smoke.
A growing regulatory movement is now accelerating the shift toward smoke-free operating environments, establishing a new standard of care. The United States is at the forefront of this change, with 20 states having already passed legislation mandating smoke evacuation. This regulatory tailwind is creating a significant market demand for effective and seamlessly integrated solutions.
A Novel Approach to Smoke Evacuation
Alesi Surgical's proprietary Ultravision platform offers a groundbreaking alternative to conventional methods. The technology utilizes electrostatic precipitation to actively capture and remove smoke directly at the source as it is generated. This innovative approach avoids the workflow disruptions associated with traditional suction-based systems, representing a fundamental shift in smoke management.
The first-generation Ultravision system has already demonstrated its efficacy in over 50,000 laparoscopic and robotic procedures across Europe, the US, and Japan. Independent industry studies have validated its performance, showing it removes smoke from the surgical field up to 225 times faster than competing technologies. This rapid clearance dramatically improves visibility and surgical precision.
Beyond enhancing safety for staff, the technology delivers tangible benefits for patients. It enables surgeons to operate at lower abdominal pressures, reducing CO₂ usage by up to 82% while maintaining a clear view. This technique is associated with reduced procedure times, improved patient outcomes, and faster recovery periods.
Expansion and Future Development
The company's next-generation Ultravision2 system recently gained regulatory clearance, expanding its application to open surgery procedures. This is a critical development, as existing solutions for open surgery have been particularly unpopular among surgical teams. The new system also allows for the use of Alesi's own surgical tools, which combine smoke management with tissue dissection.
According to Dr. Dominic Griffiths, Founder and CEO of Alesi Surgical, electrosurgical tools have transformed modern surgery but created the persistent problem of smoke. He stated that Ultravision2 effectively addresses this by tackling smoke at its source without compromising surgical workflow. This makes it essential for supporting the next generation of minimally invasive and robotic procedures.
Isobel Egemole, Investment Director at IW Capital, noted that surgical smoke is an increasingly important priority for hospitals focused on safety and compliance. She emphasized that Alesi Surgical's unique approach addresses the problem at its source, positioning Ultravision2 to play a key role. The firm believes the technology will be central as smoke-free operating theatres become the norm.
With this new £7 million in funding, Alesi Surgical is strongly positioned to accelerate its commercial growth and technological innovation. The investment validates the company's unique approach to a long-standing problem in surgical safety. As regulatory pressures mount and awareness grows, Alesi's Ultravision platform is poised to become an indispensable tool in operating rooms worldwide.